U.S. Markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.12
    +0.30 (+0.36%)
     
  • Gold

    1,819.20
    +2.70 (+0.15%)
     
  • Silver

    23.02
    +0.11 (+0.47%)
     
  • EUR/USD

    1.1418
    +0.0003 (+0.0228%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • Vix

    19.19
    -1.12 (-5.51%)
     
  • GBP/USD

    1.3648
    -0.0032 (-0.2306%)
     
  • USD/JPY

    114.5700
    +0.3700 (+0.3240%)
     
  • BTC-USD

    42,098.63
    -1,200.71 (-2.77%)
     
  • CMC Crypto 200

    1,010.34
    -15.39 (-1.50%)
     
  • FTSE 100

    7,611.23
    +68.28 (+0.91%)
     
  • Nikkei 225

    28,333.52
    +209.24 (+0.74%)
     

MEI Pharma's cancer drug misses main goals in mid-stage study

March 23 (Reuters) - MEI Pharma says its cancer drug failed to meet the main goal in a mid-stage study.

The drug, pracinostat, in combination with chemotherapy drug azacitidine showed no difference in complete remission in previously untreated patients with myelodysplastic syndrome (MDS) - a type of blood cancer - against azacitidine alone.

Complete remission implies the disappearance of all signs of cancer in response to treatment. It does not always constitute a cure.

(Reporting by Rosmi Shaji in Bengaluru; Editing by Saumyadeb Chakrabarty)